Orelabrutinib Followed by Response-adapted Ultra-low Dose 4Gy Radiation as First-line Treatment of MALT Lymphoma
Clinical trial NCT06583837 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06583837
- Sponsor
- Fudan University
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-09-10
- Primary completion
- 2025-08-18
- Enrollment
- 50
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.